A research project being conducted at the University of Western Australia (UWA) investigating a potential treatment for hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in the young, has secured a funding boost.
The research project has received a CSL Research Acceleration Initiative (RAI) award, which aim to fast-track the development of innovative biotherapies, to support further study into a potential treatment for the inherited heart disorder.
The award provides up to $500,000 funding and access to industry resources for the UWA research team.
Professor Livia Hool, Head of UWA’s Cardiovascular Electrophysiology Laboratory said the team was thrilled with the backing to advance the research.
“We’ve been so excited to see that our therapy looks increasingly promising as a candidate to treat hypertrophic cardiomyopathy,” Professor Hool said.
“The inherited heart disorder is the leading cause of sudden cardiac death in the young and we want to impact this by preventing the development of the hypertrophy.”
